Improving tau clearance in Alzheimer's disease by reducing a specific protein
Enhancing proteasomal activity and tau clearance via USP14 reduction in Alzheimer's Disease mouse models
This study is looking at ways to help people with Alzheimer's disease by finding a way to help their brains get rid of harmful tau proteins that can cause memory problems, using a special technique to boost the brain's natural cleanup system.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10995921 on NIH RePORTER |
What this research studies
This research focuses on Alzheimer's disease, a condition that leads to memory loss and is a major cause of dementia. The study aims to enhance the brain's ability to clear tau proteins, which accumulate and contribute to cognitive decline. Researchers will use a technique involving antisense oligonucleotides to reduce the levels of a protein called Usp14, which hinders the degradation of tau. By increasing the activity of the proteasome, the brain's waste disposal system, this approach seeks to lower tau levels and potentially slow down neurodegeneration.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease who exhibit symptoms related to tau pathology.
Not a fit: Patients with other forms of dementia that do not involve tau pathology may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively reduce tau accumulation and improve cognitive function in Alzheimer's patients.
How similar studies have performed: While the approach of targeting Usp14 for tau clearance is innovative, similar strategies using antisense oligonucleotides have shown promise in other neurological conditions.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Hu, Miwei — Washington University
- Study coordinator: Hu, Miwei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.